Insulin Degludec and Insulin Aspart
Sponsors
Huashan Hospital, Sunshine Lake Pharma Co., Ltd.
Conditions
DiabetesLiver Cirrhosis
Phase 3
Research on Optimal Strategy of Hypoglycemic Therapy for Cirrhosis With Diabetes
NCT05641337
Start: 2022-10-01End: 2025-12-30Target: 184Updated: 2022-12-07
A Study of Insulin Degludec/Insulin Aspart Biosimilar (22011) Compared With Insulin Degludec/Insulin Aspart(Ryzodeg) in Participants With Type 2 Diabetes in China
CompletedNCT05802862
Start: 2023-07-06End: 2024-08-16Updated: 2026-05-01